Variables | Total | P-value | NIPPV prior to IMV | Only IMV | P-value | |
---|---|---|---|---|---|---|
All Patients | N=54 Deaths 44 [81.5%] |
N=27 Deaths 23 [85.2%] |
N=27 Deaths 21 [77.8%] |
0.73 | ||
Deaths/n | Deaths/n | Deaths/n | ||||
BMI <26.9 26.9+ |
20/27 [74.1%] 24/27 [88.9%] |
0.29 |
9/12 [75.0%] 14/15 [93.3%] |
11/15 [73.3%] 10/12 [83.3%] |
1.00 0.57 |
|
Age <65 65+ |
16/22 [72.7%] 28/32 [87.5%] |
0.28 |
5/9 [55.6%] 18/18 [100.0%] |
11/13 [84.6%] 10/14 [71.4%] |
0.18 0.028 |
|
Gender Female Male |
19/24 [79.2%] 25/30 [83.3%] |
0.74 |
11/13 [84.6%] 12/14 [85.7%] |
8/11 [72.7%] 13/16 [81.3%] |
0.63 1.00 |
|
ILD Subtype IPF CTD Sarcoidosis Other |
8/8 [100.0%] 13/17 [76.5%] 2/7 [28.6%] 21/22 [95.5%] |
0.001 |
2/2 [100.0%] 6/8 [75.0%] 2/4 [50.0%] 13/13 [100.0%] |
6/6 [100.0%] 7/9 [77.8%] 0/3 [0.0%] 8/9 [88.9%] |
1.00 1.00 0.43 0.41 |
|
ILD Presence <1 year ≥1 year |
22/24 [91.7%] 22/30 [73.3%] |
0.16 |
11/11 [100.0%] 12/16 [75.0%] |
11/13 [84.6%] 10/14 [71.4%] |
0.48 1.00 |
|
Pulmonary Hypertension Present Not Present |
23/28 [82.1%] 21/26 [80.8%] |
1.00 |
10/14 [71.4%] 13/13 [100.0%] |
13/14 [92.9%] 8/13 [61.5%] |
0.33 0.039 |
|
History of Connective Tissue Disease Present Not Present |
18/27 [66.7%] 26/27 [96.3%] |
0.011 |
10/14 [71.4%] 13/13 [100.0%] |
8/13 [61.5%] 13/14[92.9%] |
0.69 1.00 |
|
Cause of ARF Pneumonia/Sepsis ILD Exacerbation All others |
28/33 [84.8%] 9/9 [100.0%] 7/12 [58.3%] |
0.45 |
14/17 [82.4%] 6/6 [100.0%] 3/4 [75.0%] |
14/16 [87.5%] 3/3 [100.0%] 4/8 [50.0%] |
1.00 1.00 0.58 |
|
SVTs Sinus Tachycardia All Other SVTs |
15/21 [71.4%] 24/25 [96.0%] |
0.037 |
6/7 [85.7%] 14/15 [93.3%] |
9/14 [64.3%] 10/10 [100.0%] |
0.61 1.00 |
|
Vasopressor Used Not used |
38/44 [86.4%] 4/8 [50.0%] |
0.035 |
19/22 [86.4%] 2/3 [66.7%] |
19/22 [86.4%] 2/5 [40.0%] |
1.00 1.00 |
|
Pulmonary Vasodilator Used Not Used |
19/22 [86.4%] 19/26 [73.1%] |
0.31 |
6/8 [75.0%] 13/15 [86.7%] |
13/14 [92.9%] 6/11 [54.5%] |
0.53 0.09 |
|
Steroid Use Pulse/Stress Dose Other Dose |
20/22 [90.9%] 18/26 [69.2%] |
0.08 |
12/13 [92.3%] 11/14 [78.6%] |
8/9 [88.9%] 7/12 [58.3%] |
1.00 0.40 |